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Abstract 
The aim of this research was to functionally assess changes in cortical 5-
hydroxytryptamin~ ( 5-HT ~ receptors following exposure to drugs used to treat 
depression or to electroconvulsive shock. The literature suggests a possible role 
for 5-HT 2A receptors in the onset and treatment of depression but, to date, no 
extensive functional assessment of cortical 5-HT 2A receptors has been undertaken 
to determine how important a role this plays. 
N-methyl-0-aspartate (NMDA) depolarizes cortical neurons and this 
depolarization is enhanced by 5-HT acting at 5-HTZA receptors. Using this 
facilitation as a measure of 5-HT 2A receptor activity the functionality of 5-HT2A 
receptors on cortical neurons was assessed following acute and chronic exposure 
to imipramine, fluoxetine or mianserin. These results were compared with those 
following a course of electroconvulsive treatment (ECT). 
The results showed that following chronic ( 14 day), but not acute (2 day) 
exposure to imipramine and fluoxetine, the 5-HT concentration response 
relationship was shifted to the right and exhibited a lower maximum response 
compared to controls. In contrast, mianserin, a 5-HT 2A receptor antagonist which 
also exhibits antidepressant efficacy, produced a similar shift and reduced 
maximum following acute exposure. ECT did not alter the 5-HT concentration-
Ul. 
response relationship. Neither drug exposure nor ECT significantly altered NMDA 
responses. 
Based on these results it is concluded that cortical 5-HT 2A receptor down-
regulation may be an important event in mediating the therapeutic response 
achieved following chronically administered antidepressants. 5-HT 2A receptor 
down-regulation may shift the balance from excitatory 5-HT 2A receptors in favor 
of inhibitory 5-HT1A receptors, co-localized on postsynaptic cortical neurons. 
Thus, a rise in synaptic 5-HT levels following chronic antidepressant treatment 
increases the activity of postsynaptic 5-HT1A receptors and results in an increase 
in inhibitory 5-HT neurotransmission. A rise in inhibitory 5-HT neurotransmission 
could counteract the increase in excitatory 5-HT activity thought to occur in 
depressed individuals. This represents a return in net 5-HT activity to a 
homeostatic level, alleviating symptoms associated with depression. 
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Chapter 1 
Introduction 
1.1 Depression: 
Depression can be divided into two types, exogenous and endognous (for 
review see Kandel et al.. 1991 ). Exogenous depression is thought to result from 
a specific stress, such as the loss of a family member, loss of a job, or transient 
loss of health. It reflects an intensification of the normal response to a disturbing 
circumstance. Individuals who suffer from this type of depression appear to have 
an existing predisposition to depressive behavior. An important aspect of 
exogenous depression that differentiates it from endogenous depression is that the 
former condition does not respond to antidepressant treatment. 
Endogenous depression is a debilitating disease which affects 
approximately 30% ofthe adult population during their lifetime (Klerman, 1987). 
Approximately 40 to 60% of individuals suffering from endogenous depression 
require hospitialization. Unlike exogenous depression, endogenous depression 
does not appear to result from an external event. There are five common features 
associated with endogenous depression: 1) diurnal variations in depression; 
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2) alteration of sleep patterns; 3) appetite changes and weight gain or loss; 4) 
psychomotor difficulties; 5) lack of interest. 
Individuals who suffer from endogenous depression have symptoms which 
persist from 4 to 12 months and gradually abate if left untreated (Richelson, 
1994). Endogenous depression appears to be cyclic, depressive episodes have a 
high probability of recurrence .. The severity of the condition is indicated by 
statistics showing that 30% of those suffering from endogenous depression 
commit suicide (Richelson, 1994 ). In addition to individual suffering, people who 
are afflicted with endogenous depression have a negative impact on families, 
friends and employment (Mendels, 1992). 
The likelihood of an individual incurring a depressive episode is 2-3 times 
higher in women than in men suggesting an underlying biological component. 
(Mendels, 1992; Richelson, 1994). Additional evidence for a genetic component 
is that those who have first degree relatives that suffer from depression have a 
higher incidence of developing depression than individuals who do not 
(Richelson, 1994 ). 
The annual cost of depression in the United States has been estimated to 
be 43.7 billion dollars, which includes direct treatment costs and indirect costs of 
suicide and loss in the workplace (Greenberg et al. , 1993). Given the population 
3 
size of Canada, this would equate to an impact of approximately 4 billion dollars 
annually in Canada. 
1.2 Treatment of Depression: 
Although depression (melancholia) has been recognized for a long time, 
effective pharmacological treatment only began in the early 1960's (Pletscher, 
1991 ). The frrst generation of antidepressant drugs were discovered 
serendipitously. Iproniazid, which was used in the treatment of tuberculosis (Fox 
et al, 1953), was observed to reverse the depression exhibited by patients treated 
with reserpine for hypertension (Brodie et al., 1966). Iproniazid inhibits 
monoamine oxidase (MAO) which metabolizes monoamines such as 
norepinephrine (NE), 5-hydroxytryptamine (5-HT) and dopamine (Pletscher, 
1991). Shortly thereafter another group of drugs, known as the tricyclics,were 
identified. These drugs undergoing evaluation for the treatment of schizophemia 
were observed to reverse the depressive symptoms induced by reserpine in the 
treatment of schizophemia (Meltzer, 1992). Research into both these agents led 
to the development of the first generation of antidepressant drugs. 
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Although both monoamine oxidase inhibitors (MAOis) and tricyclic 
antidepressants (TCAs) are efficacious in the treatment of depression there are 
serious side effects which limit their use. Cardiotoxicity and overdose, leading to 
tissue damage and sometimes death, are associated with the use of TCAs. 
Hypertension and hepatic necrosis are associated with the use of MAOis 
(Leonard, 1996). These side effects are due, in part, to the wide spectrum of action 
exhibited by these agents on multiple neurotransmitter systems including the 
cholinergic, histaminergic, serotonergic and adrenergic systems (Hollister and 
Claghom, 1993 ). Side effects and the lack of therpeutic effectiveness in some 
patients prompted researchers to re-evaluate the use of MAO Is and TCAs and 
search for more efficacious treatment paradigms. 
Selective serotonin re-uptake inhibitors (SSRis) formed the second 
generation of antidepressants and became clinically important in the early 1980s 
(Hyttel, 1994 ). As the name implies these drugs were more selective for the 
serotonin transporter than either the norepinephrine or dopamine transporter. A 
major benefit of these drugs is their low affinity for muscarinic, adrenergic, 
histaminergic, GABAergic and serotonergic receptors (Hollister and Claghom, 
1993 ). Thus, many of the side effects associated with the use of MAO Is and 
TCAs are reduced or eliminated. 
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Continuing research on MAO revealed that MAO could be divided into 
two subtypes, MAO-A and MAO-B (Leonard, 1996). They are distinguished by 
their substrate preference and inhibitor specificity. Thus, NE and 5-HT are 
catabolized by MAO-A while dopamine is catabolized by both forms of MAO 
(Blier et al., 1990; Yang and Neff, 197 4 ). With the advent of inhibitors selective 
for the MAO subtypes and, as a consequence, a reduction in side effects, there has 
been a resurgence of the use of MAO Is in the treatment of depression (Leonard, 
1996). 
Other treatment paradigms for depression include lithium and 
electroconvulsive shock therapy (ECT). Lithium has been used in the treatment 
of depression since the observation in the early 1970s that depressed patients show 
improvement in their mood when treated with lithium (Goodwin and Post, 197 4 ). 
Lithium, however, is associated with serious side effects and high toxicity 
(Gelenberg, 1988). 
Although ECT is used for the treatment of depression it is associated with 
side effects of which the most serious is memory impairments (Coleman et al., 
1996). These side effects prevent its widespread use.Though ECT has been used 
for over 50 years, the basis of its therapeutic action remains unknown (Fink, 
1990). 
6 
Despite the success of MAOls, TCAs. SSRis, lithium and ECT there 
remains a 14 to 21 day time-lag between the start oftherapy and the onset of 
therapeutic effect despite an apparent immediate pharmacological effect of the 
drugs, e.g. blocking the 5-HT uptake or MAO, (Blackshear and Sanders-
Bush, 1982; Borsini, 1994; Oswald et al., 1972). 
From this brief review it may be concluded that several neurotransmitter 
systems are potentially involved in the pharmacological treatment of depression. 
This offers the possibility that a combination of approaches may result in more 
efficacious treatment and, possibly, a reduction in the time lag between the start 
of therapy and the reduction in symptoms. The key to more efficacious treatment 
lies with a better understanding of the mechanisms underlying the present 
treatment paradigms. 
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1.3 Neurotransmitters and Depression: 
Although depression is an age old medical condition the bridge between the 
onset of depression and the mechanisms that underlie depression only began to be 
understood in the early 1960's, when the benefits of using chemotherapy to treat 
depression were first recognized (Pletscher, 1991 ). These chemotherapeutic 
treatments affected a number of neurotransmitter systems which include NE (Pare 
and Sandler, 1959; Schildkraut, 1965); dopamine (Randrup et al., 1975) and 5-HT 
(Coppen, 1967). Although these were the first neurotransmitter systems 
investigated for their potential roles in depression, more recently a possible link 
has been shown with others, including GABAergic (Emrich et al., 1980), 
histaminergic (Green and Maayani, 1977), muscarinic (Sydner and Yamamura, 
1977) and glutaminergic systems (Trullas and Skolnick, 1990). 
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1.4 Catecholamine Hypothesis of Depression: 
A role for NE and dopamine, both catecholamines, in the etiology of 
mental illnesses has been postulated since the late 1950's. Based on observations 
with reserpine, MAOis and imipramine-like drugs, Schildkraut (1965) advanced 
the catecholamine hypothesis. He proposed that some, if not all, forms of 
depression are associated with an absolute or relative deficiency of 
catecholamines, particularly NE, at functionally important adrenergic receptor 
sites in the brain. 
Reserpine, which is isolated from the Indian plant Rauwolfia serpentinia, 
was formerly used clinically in the treatment of hypertension (Pletscher, 1991). 
Reserpine facilitates the release ofNE, dopamine and 5-HT from storage vesicles 
(Sugrue, 1983). Thus, release ofNE by reserpine and its subsequent enzymatic 
degradation by MAO ultimately results in a deficiency of endogenous NE (Kopin, 
1964; Kopin, 1982; Von Euler et al., 1964 ). The association between reserpine and 
depression is supported by the observation that approximately 15% of all 
individuals treated for hypertension with reserpine exhibit depressive symptoms 
(Faucett et al., 1957; Jensen, 1959; Lemieux et al., 1956). Further evidence linking 
the effects of reserpine treatment to depression came from the 
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observations that: 1) a higher incidence of depression is seen in patients taking 
reserpine than is seen with other antihypertensives; 2) the larger the dose of 
reserpine, the higher the incidence of depressive reactions; 3) the depression 
usually clears when reserpine treatment is stopped, but returns if the drug is 
restarted (Bunney and Davis, 1965). 
The focus of the catecholamine hypothesis on NE results, in part, from the 
effects ofNE in the brain. The principal site ofNE synthesis is the locus coeruleus 
which has a dense projection to many areas of the brain including the 
hypothalamus, hippocampus and cerebral cortex (Bremner et al., 1996), areas 
important for mood, arousal and psychomotor functions (Moore and Bloom, 
1979). Given this, a potential involvement ofNE in depression is not surprising. 
Iproniazid was first synthesized in the early 1950s from isoniazid (Fox et 
al., 1953 ). It was developed to be a more effective treatment paradigm for 
tuberculosis but, as noted earlier, became very important in the treatment of 
depression (Pletscher, 1991 ). Use of iproniazid as an antidepressant began 
serendipitously when it was observed that iproniazid blocked the reserpine 
response (Pletscher, 1991 ). Thus, the sedation and lethargy produced with 
reserpine was replaced by excitation when iproniazid was administered (Brodie 
et al., 1966). Moreover, non-depressed patients receiving iproniazid for the 
10 
treatment of tuberculosis experienced euphori~ psychomotor stimulation and 
psychostimulation (Pletscher et al., 1960). Clinical studies using iproniazid as a 
treatment for depression were conducted on individuals diagnosed with stable 
depression for more than twenty years. Approximately 70% of the patients treated 
with iproniazid showed improvement. Thus, the first clinical drug for the 
treatment of depression was established (Pletscher, 1991 ). 
Imipramine was discovered in the 1950s as a derivative ofthe tricyclic 
compound chlorpromazine, used in the treatment of schizophrenia (Pletscher, 
1991 ). Though imipramine was ineffective in the treatment of schizophrenia it 
was found to be beneficial in treating depression (Kuhn, 1958). By blocking 
reuptake ofNE, imipramine acts to increase the amount ofNE in the synaptic 
cleft by inhibiting re-upta.ke intoNE terminials (Sugrue, 1983). Moreover, like 
iproniazid, imipramine blocks reserpine-induced depression (Pletscher, 1991 ). 
Although observations with reserpine, iproniazid and imipramine 
implicated the noradrenergic system with respect to the onset and treatment of 
depression, the notion of a simple deficiency ofNE had to be abandoned. A major 
problem with the catecholamine hypothesis is its failure to explain the delayed 
therapeutic response (Borsini, 1994; Oswald et al., 1972). Fourteen to 21 days are 
required to observe the beneficial effects of drug therapy, whereas the blockade 
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of re-uptake of NE or the inhibition of MAO occurs almost immediately. This 
resulted in a shift away from the pre-synaptic focus of the catecholamine 
hypothesis to a focus on the importance of post-synaptic effects. 
One of the most consistently observed responses to chronic antidepressant 
treatment has been the down-regulation of the (3- adrenergic receptors (Sulser et 
al, 1983). Virtually every class of antidepressant treatment including ECT has this 
effect in the cortex (Caldecott-Hazard et al., 1991 ). 
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1.5 5-HT and Depression: 
The idea that the onset of depression results from an irregularity of the 5-
HT system was first examined in the late 1960s. Based on the disturbances in 
amine metabolism it was postulated that depression resulted from a deficiency in 
the 5-HT system (Coppen, 1967; Lapin and Oxenkrug, 1969). Coppen (1967) 
observed that tryptophan, a precursor of 5-HT, potentiates the antidepressant 
effect seen with MAO Is. Coppen ( 1967) also noted that in depression, tryptamine 
excretion decreases and lower levels of 5-hydroxyindole acetic acid (5-HIAA), a 
metabolite of 5-HT, are found in the cerebrospinal fluid (CSF). Post-mortem 
studies on depressed patients revealed decreased levels of both 5-HT and 5-HIAA 
when compared to individuals who were not diagnosed with depression when they 
died (Lloyd et al., 1974). Examination ofCSF using baseline measures of5-HIAA 
and postprobenecid 5-HIAA levels (probenecid inhibits efflux of 5-IDAA from 
CSF), revealed that the level of 5-HIAA was reduced in patients suffering from 
depression (Asberg et al., 1976; Goodwin and Post, 1977; Sjostrom, 1973). These 
results suggest that 5-HT turnover is reduced. More importantly, the decreased 
levels of 5·HIAA were only observed in individuals who were diagnosed with 
endogenous depression (Van Pragg et al., 1971). 
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Precursor depletion experiments also support the involvement of 5-HT in 
depression. Tryptophan~ an essential amino acid, is the precursor for 5-HT 
synthesis (Gal and Dress, 1963; Tagliamonte et al., 1973). Dietary depletions of 
tryptophan reduce 5-HT activity (Delgado et al., 1990). Moreover. acute 
depletion of tryptophan reversed the therapeutic benefits of antidepressant 
treatment in depressed patients, but they returned to the remitted state on return 
to regular food 24 to 48 hours later (Delgado et al., 1990). 
Studies examining the effects ofTCAs and MAOis show that they have 
effects just as profound on 5-HT transmission as they have on NE transmission 
(Caldecott-Hazard et al., 1991 ). MAO Is reduce 5-HT catabolism and hence 
increase 5-HT transmission, due to the increased 5-HT concentration in the 
synaptic cleft (Caldecott-Hazard, 1991 ). In the same vein, imipramine inhibits 
both NE and 5-HT re-uptake from the synaptic cleft (Byrant and Brown, 1986). 
Two important experiments m the 1970s showed that 
parachlorophenylalanine (PCPA), a 5-HT synthesis inhibitor, appears to reverse 
the antidepressant effectiveness of both imipramine (Shopsin et al., 1975) and 
tranylcypromine (Shopsin et al., 1976) within 24 hours of administration. This 
suggests that 5-HT must be available for antidepressants to exert their therapeutic 
effect. 
14 
The continued development of new antidepressants with increasingly 
greater selectivity for the 5-HT transporter over the NE transporter is consistent 
with a role for 5-HT in depression. Importantly, all serotonin selective re-uptake 
inhibitors (SSRis) are efficacious in the treatment of depression and the only 
common feature among the SSRis is their ability to block the uptake of 5-HT 
(Blier and De Montigny, 1994 ). 
1.6 Role of 5-HT Receptors: 
As with the catecholamine hypothesis, the failure of a simple monoamine 
deficiency theory to explain the delayed clinical response to antidepressants has 
shifted the focus of antidepressant research from presynaptic to postsynaptic 
events (Yates et al., 1990). 
It has been proposed that 5-HT1A receptors are involved in both the onset 
of depression and its treatment (Stahl, 1994). Physiologically, 5-HT1A receptors 
mediate the 5-HT induced release of adrenocortotrophic hormone (ACTH) and 
cortisol along with a pronounced hypothermic response (Lesch, 1992; Lesch et al., 
1990; Stahl, 1992). Individuals diagnosed with depression have a blunted 
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hypothermic response and decreased release of ACTH in response to the 
administration of 5-HT1A partial agonists, such as buspirone or gepirone (Lesch, 
1992; Stahl, 1992). This suggests that 5-HT1A receptors may be down-regulated 
or desensitized in clinically depressed patients. There is a partial reversal of the 
neuroendocrine impairment following chronic antidepressant treatment (Newman 
et al., 1993; Stahl, 1994). Moreover, partial5-HT1A receptors agonists are effective 
antidepressants (Rausch et al., 1990). Finally, following chronic antidepressant 
treatment presynaptic somatodendritic 5-HT1A receptors are down-regulated 
(Charney et al., 1981; Stahl, 1992). Somatodendritic 5-HT IA receptors are 
inhibitory receptors which regulate the firing rate of the dorsal raphe neurons. 
These observations suggest a possible role for the 5-HT1Areceptor in the onset and 
treatment of endogenous depression but further research is needed to distinguish 
whether the receptor has a role in mediating the therapeutic response to 
antidepressants or whether the changes are merely a by-product of chronic 
antidepressant treatment. 
Another receptor of interest with regard to depression is the 5-HT2A 
receptor. In 1980, Peroutka and Snyder proposed that a common feature of 
chronic, but not acute, exposure to antidepressants was a down-regulation of 5-
HT2 binding sites in the brain. Post-mortem studies revealed a marked increase in 
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the density of frontal cortex 5-HT 2 receptors in patients who were diagnosed with 
major depression or had committed suicide (Arango et al., 1990; Arora and 
Meltzer, 1989; McKeith et al., 1987; Yates et al., 1990). Moreover, there are 
higher levels of 5-HT2A receptors on platelets of suicidal depressed individuals, 
when compared to normal or non-suicidal subjects (Biegon et al., 1990; Pandey 
et al., 1990). 
Following chronic treatment with antidepressants there is a marked 
decrease in 5-HT-stimulated inositol phosphate (IP) formation in rat cortex 
(Kendall and Nahorski, 1985). The 5-HT-stimulated IP formation is mediated via 
the 5-HT2A receptor (Conn and Sanders-Bush, 1987). Finally, in rats, chronic 
antidepressant treatment reduces wet dog shakes, a behavior mediated by the 
activation of 5-HT2A receptors (Eison et al., 1991). 
Taken together these results suggest that chronic exposure to 
antidepressants modifies 5-HT responses. However there are several lines of 
evidence indicating that modification of the 5-HT receptor system may not be the 
only important event mediating depressive onset and, later, responses to therapy. 
First, there appears to be a functional link between 5-HT, NE and dopamine 
that is evident following 5-HT depletion. Thus, cortical neurons exhibit decreased 
responsiveness to microiontophoretically applied NE and dopamine following 
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5-HT depletion (Ferron et al., 1982; Janowsky et al., 1982). Second, there appears 
to be a link between 5-HT and GABA which is also implicated in the therapeutic 
effectiveness of antidepressants (Blier et al., 1987). There is a 40% down-
regulation ofbenzodiazepine binding in the brain following chronic treatment with 
buspirone ( Gobbi et al., 1991 ). Third, ECT up-regulates 5-HT 2A binding which is 
in contrast to the usual observation with chronic exposure to antidepressants 
(Sanders-Bush et al., 1990; Sanders-Bush, 1990; Stockmeier and Kellar, 1986; 
Vetulani et al., 1981 ). 
1. 7 Rationale For Experiments: 
Following this review on the involvement of5-HT in depression, it is clear 
that there is an alteration of the 5-HT system that is manifested by an increase in 
5-HT neurotransmission mediated by an increase in 5-HT 2A receptor activation. 
More specifically, there is an apparent up-regulation of the 5-HT 2A receptor in 
individuals who suffer from depression. Assuming that this up-regulation of the 
5-HT 2A receptor is important, the treatment of patients with depression should 
involve a reduction of 5-HT 2A receptor function which would restore the brain to 
a homeostatic state. The hypothesis of this research is that following chronic, but 
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not acute, treatment with antidepressants or a course ofECT the 5-HT2A receptor 
is functionally down-regulated. This would support the importance of down-
regulating the 5-HT2A receptor in reversing the effect of a depressive episode and 
in mediating the therapeutic response. 
Previous studies examining the role of 5-HT2A receptors in depression 
including biochemical and behavioral measurements or binding studies have not 
fully addressed the functional role of5-HT2A receptors in depression. Biochemical 
tests examining IP turnover measured IP accumulation 60 min after application 
of agonists (Kendall and Nahorski, 1985), whereas 5-HT2A receptors are rapidly 
desensitized (Rahman and Neuman, 1993a). Therefore, measurement of IP 
accumulation at 60 min would not reflect activity of the undesensitized receptor. 
Wet dog shakes reflect 5-HT2A receptor activity in the brainstem and not the 
frontal cortex (Bedard et al, 1977). The 5-HT2A receptors located in the frontal 
cortex are the receptors up-regulated in depressed individuals. Thus, effects on 
behaviors mediated by 5-HT2A receptors in the brainstem are not relevant. Finally, 
binding studies lack the ability to ascertain whether the 5-HT2A receptor remains 
functional following chronic antidepressant treatment (Wamsley et al., 1987). 
In the present study the functionality of 5-HT2A receptors in the frontal 
cortex is directly assessed in brain slices using grease-gap methodology (Harrision 
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and Simmonds, 1985).This method has been employed to assess responses 
mediated by various G-protein coupled receptors including the 5-HT2A receptor 
(Rahman and Neuman, 1993). Application of 5-HT alone does not provoke a 
response (Rahman and Neuman, 1993). However, N-methyl-D-aspartate induces 
a depolarization of cortical neurons and 5-HT enhances this depolarization via an 
action mediated through the 5-HT2A receptor (Rahman and Neuman, 1993). Thus, 
changes in 5-HT2A function can be readily determined following both acute and 
chronic administration of antidepressants or following the administration ofECT. 
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Chapter 2 
Methods and Materials 
2.1 Animals: 
All procedures involving animals were in accordance with the guidelines 
of the Canadian Council of Animal Care and the Institutional Animal Care 
Committee of Memorial University. 
Male Sprague Dawley rats, 150 to 350g, were purchased from the Animal 
Care Facility. The animals were housed at the animal care unit and kept on a 12 
hour light cycle with controlled humidity and temperature. Food (Prolab Rat 
Chow) and water were provided ad libitum. 
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2.2 Wedge Preparation and Recording: 
Wedges from sensorimotor cortex were prepared with minor 
modifications, as described by Harrison and Simmonds ( 1985). Rats were 
anaesthetized with 20% urethane ( 1.5mg kg-• i.p.) and killed with a heavy blow 
to the base of the skull. The brain was rapidly removed and placed in ice cold 
( <5°C) modified artificial cerebrospinal fluid (M-ACSF). The brain was 
transferred to moist filter paper lying on a petri dish containing ice. The brain was 
blocked and fixed at its caudal end to a block using cyanoacrylate glue (Instant 
Crazy Glue). Coronal slices 500J.Lm thick were cut at 0-4°C using a Viboslicer 
(Campden Instruments Ltd., U.K.). Slices were transferred to an incubation 
chamber containing cooled M-ACSF and bubbled with 95% 0/ 5% C~. Five 
slices were retained starting slightly anterior to bregma (Paxinos and Watson, 
1986) and proceeding caudally. Following 30 min of incubation, allowing the 
cooled M-ACSF to reach room temperature (20-24°C), the medium was replaced 
withACSF. 
After an additional 60 min incubation, a slice was transferred to a petri dish 
containing ACSF. One wedge of sensorimotor cortex (approximately 1.5 nun 
wide at pial surface and 1 mm wide at corpus callosum) was cut from a slice and 
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mounted in a two compartment recording bath (Harrison and Simmonds, 1985). 
Only one wedge of sensorimotor cortex from the same dorsal-lateral position was 
used from each hemisphere. The region of the wedge containing cell bodies was 
isolated electrically from corpus callosum and projecting axons by means of a 
grease seal (high vacuum silicone grease, BDH) (Fig l ). The two compartments 
were perfused separately at 2 mVmin via a peristaltic pump (Masterflex Pump, 
Cole Palmer, USA). Application ofNMDA to the cell body/dendrite containing 
compartment resulted in a depolarization which was recorded with respect to the 
corpus callosum using Ag!AgCl electrodes embedded in 3% agar containing IM 
NaCl. The electrodes were connected to a high impedance amplifier (3db down 
at 1 Hz) and the recorded potential displayed on a Kipp and Zonnen chart 
recorder. 
2.3 Composition of ACSF 
ACSF had the following composition (mM): NaCl 126, KCI 3.5, CaCI2, 2, 
MgCh, 1.3, NaH2P04, 1.2, NaHC03 25, glucose 11, myo inositol5. In M- ACSF, 
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Figure 1: Schematic diagram of cortical wedge postioned in two compartment 
recording chambers (Rahman, 1994 ). The stippled area on cortex is the grease seal 
separating the two compartments. Drugs were only applied to the side labled 
cortex. C. C. Corpus Callosum. See text for details. 
D.C. Amplifier 
OUT 
Chart 
Recorder 
Ag/AgCI 
cc 
IN 
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Cortex 
IN 
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NaCl was replaced by iso-osmotic sucrose and no myo inositol was present. 
(Aghajanian and Rasmussen~ 1989). ACSF was aerated with 95% 0/5% C02 and 
had a pH of7.4. 
2.4 Drug Application: 
Both 5-HT and NMDA were dissolved in ACSF and applied via a 3 way 
valve system. NMDA applications were controlled by a computer program such 
that NMDA was applied for 2 min at 20 min intervals. Previous work has shown 
that 50 J.LM NMDA yielded the optimal facilitation when co-applied with 5-HT 
(Rahman and Neuman~ 1993) and this concentration was used throughout the 
study. Co-application of 5-HT and NMDA was achieved by manually switching 
the valve for 2 min. 5-HT was diluted in ACSF just prior to application to reduce 
oxidation. The enhancement induced by 5-HT exhibits long term desensitization 
(Rahman and Neuman, 1993a). Therefore, 5-HT was administered once to each 
wedge. Drug concentrations were calculated as a salt. Stock solutions were kept 
frozen until use. 
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2.5 Antidepressant Administration: 
Antidepressants were delivered by osmotic mini-pumps (Alzet, Palo Alto, 
CA) at doses comparable to those reported in the literature. Antidepressants 
examined were imipramine, 10 mglkg, mianserin, 2 mglkg and fluoxetine, 1 0 
mglkg. Imipramine and mianserin were dissolved in saline and fluoxetine was 
dissolved in dimeth1y sulfoxide (DMSO). Antidepressant treatment was acute ( 
2 days) or chronic (14 days). Control groups consisted of 14 day treatment with 
vehicle (saline or DMSO) to insure that simply implanting the osmotic mini-pump 
did not alter the response to 5-HT. The dose delivered by the pump was based on 
a final weight of 300 grams for both acute and chronic treatment groups The 
osmotic pump was removed and one day was allowed for washout before the 
animal was sacrificed and cortical slices prepared. 
2.6 Osmotic Mini-Pumps: 
Using sterile procedures osmotic mini-pumps (Alzet, Palo Alto, CA) were 
filled with appropriate solutions and then re-weighed to insure that the pump was 
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properly filled. After filling the pump was warmed to 37 oc in a vial containing 
saline for four hours prior to implantation to allow the pump to start pumping 
before implantation. 
Pump implantation was accomplished in a rat anaesthetized with sodium 
pentobarbital (60 mglkg). An incision was made along the dorsal neckline and a 
subcutaneous pocket was made between the shoulders. The osmotic pump was 
placed in the pocket and the incision was sutured (4-0 Sofsilk Sutures). The 
animal was placed under a heat lamp and allowed to recover. Following recovery 
the rat was returned to the animal care facility. 
Following either 2 or 14 days the animal was again anaesthetized and the 
osmotic pump removed. All treatment groups were re-weighed following the 
removal of the pump and exhibited normal weight gain over the time course of 
treatment with the antidepressant (see table 2 at end of results). The animal then 
was returned to the animal care facility for one more day prior to preparation of 
slices and recording. 
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2.7 Electroconvulsive Treatment (ECT): 
Animals were lightly anaesthetized with sodium pentobarbital ( 60mg/kg) 
prior to ECT. After placing two clips on the animal's ears, a 100 volt A. C shock 
was administered for a duration of 1.5 sec. This was sufficient to induce tonic or 
tonic-clonic seizure activity. Treatments were administered every three days over 
15 days. One day following the last treatment 5-HT2A receptor functionality was 
examined. For the sham group the animals were anaesthetized and the clips were 
applied but no shock was administered. 
2.8 Data Analysis : 
Drug responses were quantified using the amplitude of the agonist-induced 
depolarization. Each response to the co-application of NMDA and 5-HT was 
normalized to percent of control, i.e. [(Treatment/Control) x 100]. The data were 
then log-transformed for analysis. This is necessary as the untransformed data are 
not normally distributed (Rahman and Neuman, 1993a). Multiple planned 
comparisons were analyzed by one way analysis of variance (Instat, Graph Pad 
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Software) followed by the Bonferroni test if the F value was significant. Data are 
presented as the antilog of the geometric mean. The standard error of the mean 
of the logarithmic data is not symmetrical when transformed so the larger value 
was used. Differences between means with "p" values less than 0.05 were 
considered significant. 
2.9 Drugs: 
The following drugs and chemicals were used: 5-hydroxytryptamine 
bimaleate (5-Hn, N-methyl-0-aspartate (NMDA) and dimethyl sulfoxide 
(DMSO) (Sigma); fluoxetine hydrochloride (gift from Eli Lilly); imipramine 
hydrochloride and mianserin hydrochloride, (Research Biochemicals Inc.). 
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Chapter 3 
Results 
3.1 Effects of 5-HT on NMDA Depolarization: 
Co-application of 5-HT with NMDA enhances the NMDA induced 
depolarization (Mally et al., 1991; Nedergaard et al., 1986; Rahman and Neuman, 
1993; Reynolds et al., 1988). This enhancement is mediated via the 5-HT 2A 
receptor (Rahman and Neuman, 1993). Application of 5-HT alone does not result 
in a depolarization (Rahman and Neuman, 1993). In keeping with previous 
studies, co-application of 5-HT (30J.1M) and NMDA (SOJ.LM) for 2 minutes 
resulted in a depolarization significantly larger in amplitude than the NMDA 
control (Fig 2). The NMDA response returned to control level following a 20 min 
wash. 
Construction of a concentration-response curve for 5-HT yielded a biphasic 
curve in which the facilitation increased from 10 to 30 J.LM 5-HT, but was reduced 
at 50 J.LM (Fig 3). The extent of the facilitation and the biphasic nature of the 
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Figure 2: 5-HT facilitates the NMDA induced depolarization of rat cortical 
neurons. Agonist application is for 2 minutes which is indicated by box under 
record. Note that NMDA depolarization returns to control magnitude following 
20 minute washout Note the delay between drug application and response results 
from the dead volume of the bath and associated tubing. 
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Figure 3: Magnitude of the 5-HT induced facilitation ofNMDA depolarizing 
response is concentration dependent. Concentration-response relationship for 5-
HT was determined at fixed test concentration ofNMDA (50J.LM). 3 to 15 wedges 
(animals, n=20) were used for each point.*, p<0.05, **, p<O.Ol, ***, p<O.OOl, 
treatment vs. control. The abscissa is logarithmic scale 
350 
300 
*** 
I -•- Control I 
*** 
I -0 250 .c c: 0 u 
< 0 
* ~ 
z 200 
~ 
0 
-;!!. 
150 
T 
100 
15 20 30 40 50 
5-HT Concentration [J.I.M] 
35 
concentration-response relationship is consistent with previous observations 
(Rahman and Neuman, 1993). The downward shift in the curve at elevated 
concentrations of 5-HT reflects desensitization of the 5-HT 2A receptor (Rahman 
and Neuman, 1993a). 
3.2 Imipramine: 
Since imipramine was diluted in saline and administered by osmotic pump, 
experiments were conducted to examine the effect of the pump and vehicle alone 
over a 14 day administration. The results showed that over a selected 5-HT 
concentration range (20 J.1M to 50 JlM} there was no significant difference 
between exposure to 14 days of saline or the matched controls (Fig 4). The other 
vehicle used in this study, DMSO, also had no significant effect following 14 day 
exposure (Fig 4 ). Since no significant difference was found between the two 
vehicle groups and the control group the data were combined to construct a new 
concentration-response control curve labeled control 2 (Fig 4 ). This control was 
used for comparison with imipramine and the other drugs used in this study. 
In slices of cortex prepared from animals treated for 14 days with 
36 
Figure 4: 5-HT enhancement of the NMDA induced depolarizations is not 
signignificantly altered by 14 days exposure to osmotic mini-pumps filled with 
DMSO or Saline. Combination of untreated control (3 to 15 wedges) and vehicle 
groups ( 4 wedges for each vehicle) were used in the construction of a new 
concentration-response curve (Control 2). 3 to 23 wedges were used in new 
concentration-response curve titled Control 2 which is used as comparision to 
NMDA facilitation by 5-HT following antidepressant exposure. 5 to 7 animals 
were used in vehicle groups. Abscissa is logarothmic scale. 
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imipramine there was a significant reduction observed in the 5-HT facilitation of 
NMDA responses from imipramine treated animals compared to that of controls. 
Exposure to imipramine for 14 days elicited a dramatic shift to the right and a 
lower maximum of the 5-HT concentration-response relationship (Fig 5). 
Despite the lower maximum and shift to the right the biphasic nature of 
the concentration-response relationship was maintained. In contrast to chronic 
treatment, imipramine treatment for 2 days did not shift the 5-HT concentration 
-response relationship or significantly lower the maximum response (Fig 5). 
Imipramine has been shown to reduce 5-HT2 binding following chronic 
treatment, but not acute treatment (Peroutka and Synder, 1980). Thus, 
modification of the response to 5-HT might simply reflect a change in available 
5-HT 2A receptors. 
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Figure 5: Fourteen, but not two day, treatment with imipramine shifts the 
concentration response relationship for the facilitation of NMDA responses 
induced by 5-HT. 3 to 5 wedges were used for each point. **, p<O.O !.(significant 
from matched control) •, p<0.05. (significant from baseline). 4 to 6 animals used 
in imipramine group. Abscissa is logarithmic scale. 
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3.3 Fluoxetine: 
Not all antidepressants alter the binding to 5-HT 2A receptors as does 
imipramine. If down-regulation of functional 5-HT 2A receptor activity is important 
for mediating the therapeutic response of antidepressants then antidepressants 
which fail to significantly alter 5-HT 2A binding should still be effective in down-
regulating functional activity at the 5-Hf 2A receptor. Fluoxetine is one of the most 
commonly prescribed antidepressants and yet in binding studies it produces either 
small decreases or no effect on binding at 5-HT !A receptors (Fuxe et al., 1983 ). 
Fluoxetine was examined using the same paradigm as used for imipramine. 
Slices of cortex prepared from animals treated for 14 days with fluoxetine 
exhibited a profound shift to the right and a significant reduction in the maximum 
of the 5-HT concentration-response relationship (Fig 6). Thus, the response to 
fluoxetine resembled the response to imipramine despite the fact that fluoxetine 
has little effect on 5-HT2A binding (Fuxe, 1983). The response to 30 f.1M and 50 
J.tM 5-HT following chronic fluoxetine exposure was significantly different from 
that of their matched controls (Fig 6). As well, none ofthe 5-HT concentrations 
employed resulted in a significant enhancement of the NMDA response after 
fluoxetine exposure (Fig 6). 
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Figure 6: Fourteen day treatment with fluoxetine, but not two days shifted the 
concentration response relationship for the facilitation of NMDA responses 
induced by 5-HT. 5 to 8 wedges were used for each point. •, p<0.05, •••, 
p<O.OOI. Significant from matched controls (control curve 2). 5 to 6 animals were 
used in fluoxetine group. Abscissa is logarithmic scale. 
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In contrast to chronic treatmen~ fluoxetine treatment for 2 days did not 
shift the 5-HT concentration-response relationship or result in the lowering of the 
maximum response (Fig 6). The washout time was 24 hours after the pump was 
removed in both the acute as well as the chronically treated rats. Thus, the shift in 
the concentration-response curve observed in chronically treated animals does not 
represent a residual action of fluoxetine on 5-HT uptake since the curve for 
acutely treated animals did not shift. 
Since the functionality of the 5-HT 2A receptor was assessed by examining 
enhancement of the NMDA response it remains possible that the NMDA receptor 
complex was altered by chronic antidepressant treatment (Nowak et al., 1993) and 
not modification of signal transduction related to the 5-HT 2A receptor. However, 
neither fluoxetine nor imipramine exposure altered the amplitude of the NMDA 
response when compared to the NMDA response in untreated animals (Table l). 
This suggested that the NMDA receptor was not altered by chronic exposure to 
the imipramine and fluoxetine. 
Furthermore, in a few wedges, muscarinic facilitation ofNMDA responses 
was examined following chronic fluoxetine treatment (Payne and McNeil, 
unpublished) and did not appear to differ from that reported previously (Rahman 
and Neuman, 1993). Therefore, effects observed following the exposure to 
Table 1: NMDA (50 J.lM} Depolarization Following Treatment with 
Imipramine or Fluoxetine. 
Treatment Size (mV)±S.E. N 
Untreated Control 3.9±0.4 62 
2 Day Imipramine 3.4±0.8 19 
l4Day 3.8±0.6 13 
Imipramine 
2 Day Fluoxetine 3.1±0.5 24 
l4Day 4.2±0.9 22 
Fluoxetine 
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fluoxetine and imipramine are thought to result from alterations of 5-HT 2A 
receptor signal transduction and not from changes in the NMDA receptor 
complex. 
3.5 Mianserin: 
Mianserin is an antidepressant which antagonizes the action of 5-HT (Maj 
et al, 1978 ; V argaftig et al., 1971) and has a high affinity for the 5-HT 2 binding 
site (Blackshear et al., 1981; Peroutka and Snyder, 1981 ). Previous studies with 
mianserin showed a rapid down-regulation of 5-HT2 receptor function following 
exposure (Blackshear and Sanders-Bush, 1982). Mianserin, like other 
antidepressants, requires 14 to 21 days before effectively reducing the symptoms 
of depression (Blackshear and Sanders-Bush, 1982). Thus, it was important to 
assess whether mianserin rapidly down-regulated cortical 5-HT2A function as 
measured in the present paradigm. 
In slices of cortex exposed to mianserin for two days there was a dramatic 
shift to the right of the concentration-response relationship and a significant 
lowering of the maximum facilitation (Fig 7). Indeed, co-application of 5-HT, 30 
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Figure 7: Failure of5-HT to significantly enhance the NMDA response following 
acute treatment with minaserin. Four wedges were used for each point ( animals, 
n=S). None of the responses to 5-HT in tissue prepared from mianserin exposure 
were significantly different from control. Abscissa is logarithmic scale. 
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J,LM, to 50 J.LM with NMDA following 2 day exposure to mianserin was not 
significantly different from the NMDA control response (Fig 7). In fact the 
response to 30 J,LM 5-HT was lower than the control~ although not significantly. 
This may reflect activation of another 5-HT receptor subtype and will be discussed 
later. As in the case of imipramine and fluoxetine, treatment with mianserin did 
not significantly alter the response to NMDA compared to the untreated control. 
The results with mianserin are consistent with the observations of 
Blackshear and Sanders-Bush ( 1982) who observed a reduction in 5-HT 2 binding 
sites following acute exposure to mianserin. The results also suggest that there is 
a direct modification of 5-HT 2A receptor signal transduction rather than a change 
in NMDA receptor function. 
3.6 Electroconvulsive Treatment: 
ECT is effective in reducing the symptoms of depression (Fink, 1990) and 
is unique in that it reportedly increases 5-HT2 binding sites following a course of 
shocks over 15 days (Sanders-Bush et al., 1990). Since an increase in 5-HT2A 
activity does not fit with the down-regulation of 5-HT 2A receptor activity observed 
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with imipramine, fluoxetine or mianserin it was important to assess whether ECT 
had any effect, functionally, on the 5-HT2A receptor following chronic 
administartion. 
In cortical slices prepared from animals exposed to 5 episodes ofECT 
administration over 15 days, no shift was observed in the concentration-response 
relationship or in the maximum facilitation induced by 5-HT compared to that of 
the sham group (Fig 8). Comparison of the NMDA response in treated versus 
sham animals revealed no significant difference. 
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Figure 8: 5-HT facilitation following ECTor Sham treated animals for IS days(S 
treatments). 4 to 6 wedges were used for each point (animals n=4). Abscisssa is 
logarithmic scale. 
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Table 2: Weight gain in animals following chronic exposure to imipramine, 
fluoxetine, saline or DMSO. 
Treatment Start( g)± Final (g)± Average Weight 
SEM SEM Gain(g)±SEM 
Fluoxetine ( 1 Omglkg) 172±18 272±21 101±5 
Imipramine (I Omglkg) 114±4 227±7 112±8 
Saline 190±21 294±19 104±4 
DMSO (50%) 223±18 334±25 111±8 
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Chapter4 
Discussion 
The aim of the present study was to assess whether chronic treatment with 
antidepressants and ECT functionally modulate 5-HT2A receptor activity in the 
frontal cortex. The results show that antidepressants reduce the facilitation 
mediated by 5-HT 2A receptor activity, whereas ECT does not. 
4.1 5-HT 2A Receptors and Antidepressants: 
Peroutka and Snyder ( 1980) showed that chronic treatment with many 
antidepressants down-regulated 5-HT2 binding. This down-regulation of 5-HT2 
binding sites following antidepressant treatment is consistent with observations 
that 5-HT 2 receptors are up-regulated in individuals diagnosed with depression. 
Therefore, antidepressants may work by counteracting the effects mediated via an 
up-regulation of the 5-HT 2A receptor that is found in individuals diagnosed with 
depression. 
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Results from the present study show that following chronic exposure to 
imipramine or fluoxetine, 5-HT induced facilitation of the NMDA depolarization 
is reduced. The apparent reduction in 5-HT 2A functional activity following 
chronic treatment with imipramine or fluoxetine cannot be attributed to residual 
drug action as the animals had a 24 hour washout period prior to sacrifice and the 
tissue was washed extensively before testing. Moreover, no loss of 5-HT activity 
was observed following acute exposure to either imipramine or fluoxetine. This 
suggests that down-regulation of the 5-HT 2A receptor following chronic 
antidepressant exposure occurs by 14 days and is consistent with the 14 day 
delayed onset of the therapeutic response exhibited by all antidepressants (Borsini. 
1994; Oswald • 1972). 
Although superficially similar. my results are not consistent with the 
observations of Peroutka and Snyder (1980) who found that chronic treatment 
with imipramine or fluoxetine reduced 5-HT2 binding sites by approximately 40% 
and 13%, respectively. In contrast, loss of functionality of the 5-HT 2A receptor 
following chronic exposure to either imipramine or fluoxetine is substantially 
greater than the moderate reductions in 5-HT2 binding sites reported by Peroutka 
and Synder ( 1980). Since a simple reduction in 5-HT 2A binding cannot account for 
my observations, a mechanism distal to the 5-HT 2A receptor must be involved. 
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Chronic antidepressant treatment alters the ligand binding properties of the 
glycine site located on the NMDA receptor complex (Nowak et al, 1993). Since 
assessment of 5-HT 2A functionality was obtained by measuring the 5-HT induced 
facilitation of the NMDA depolarization, a change in the NMDA receptor might 
account for the reduced facilitatory response observed with 5-HT. However, no 
significant difference was observed in the magnitude of the NMDA-induced 
depolarization between the control and the treatment groups. From this it is 
concluded that the decline in the 5-HT -induced facilitation ofNMDA response 
observed following chronic imipramine or fluoxetine administration probably 
results in the decline in signal transduction associated with the 5-HT2A receptor. 
Consistent with this interpretation, carbachol, acting at muscarinic receptors 
(Rahman and Neuman, 1993), continues to enhance NMDA responses in tissue 
from rats treated chronically with fluoxetine (Payne and McNeil, unpublished 
observations). Moreover, mianserin is known to rapidly reduce signal transduction 
at 5-HT2 receptors (Sanders-Bush et al., 1987) and acute administration of 
mianserin significantly reduced the 5-HT induced facilitation. 
The results with mianserin are quite different from those with imipramine 
and fluoxetine. Thus, significant down-regulation of the 5-HT 2A receptor was 
evident following acute exposure to mianserin. This acute response cannot be 
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attributed to a change in the NMDA response since there was no alteration in 
NMDA depolarization following acute exposure to mianserin. Mianserin is an 
antagonist at 5-HT2A receptors. However, 24 hrs were allowed for drug washout 
after pump removal so that a persistent presence of drug is unlikely to account for 
loss of the response to 5-HT. The present findings are consistent with those of 
Blackshear and Sanders-Bush (1982) and Sanders-Bush's group (1987) who 
reported that mianserin rapidly decreased the number of 5-HT2 binding sites and 
functionally uncoupled signal transduction at the 5-HT2A receptor as measured by 
PI turnover. Mianserin requires 14 days before it reduces symptoms associated 
with depression (Borsini , 1994; Oswald et al., 1972) so that a rapid loss of 5-HT 2 
activity alone is insufficient to account for its efficacy as an antidepressant. 
One possible explanation for delayed onset in the therapeutic response of 
mianserin may be an indirect effect on 5-HT neurons in the dorsal raphe (DR). 
Pharmacological studies have suggested that the firing rate of 5-HT neurons 
located in the DR is dependent on tonic activation by noradrenergic input 
mediated via a 1-adrenoreceptors (Haddjeri et al., 1997; Svensson et al., 1975). 
Acute exposure to mianserin may inhibit excitatory 5-HT receptors located on 
locus coeruleus neurons or neurons excitatory to locus coeruleus neurons, which 
in tum would reduce the firing rate of the DR. If this proposal is correct, then only 
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after the DR adapts and returns to normal firing (Blier et al, 1990) would the 
antidepressant effect be achieved. A more detailed description of this mechanism 
is found in the section on S-HT1A-S-HT 2A receptor interaction. 
4.2 S-HT u Receptors and ECT: 
ECT increases the number of 5-HT2 binding sites following chronic 
treatment (Fuxe et al., 1983). This is surprising since 5-HT2A binding sites are 
reportedly increased in many, but not all, studies on depressed individuals 
(Arango et al., 1990; Arora and Meltzer, 1989; McKeith et al., 1987; Yates et al., 
1990). In contrast to the binding studies, there was no significant change in the 
5-HT enhancement following a chronic course of ECT over 15 days. Once again 
the present results show a dissociation between binding and functional activity ( 
see also Wamsley). Moreover, these results suggest that functional down-
regulation of the 5-HT 2A receptor is not necessary for antidepressant efficacy. 
However, the efficacy ofECT as an antidepressant treatment has been questioned. 
Based on meta analysis, Uebersax ( 1987) suggests that no clear empirical 
evidence exists to suggest that six weeks following treatment with ECT that there 
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is any difference between patients receiving ECT and those who did not. 
Therefore, based on my results with ECT, the role of 5-HT 2A receptors in the 
events mediating the therapeutic response can not be excluded since questions 
about its validity as an effective antidepressant exist. 
4.3 Alterations in 5-HT lA Receptor Signal Transduction: 
It is well known that 5-HT 2A receptors are positively coupled to the 
phospholipase C (PLC)/ phosphoinositide (PI) hydrolysis second messenger 
system via a guanylate nucleotide binding protein (G-protein) (Chaung, 1989). 
Activation of 5-HT 2A receptors in tum activate PLC which metabolizes 
phosphoinositide 4,5- biphosphate (PIP2) to produce two second messengers, 
inositol 1,4-5 triphosphate (IP3) and diacylglycerol (DAG) (Chaung, 1989). I~ 
acting at IP3 receptors located on smooth endoplasmic reticulum releases calcium 
(Taylor et al., 1991) and DAG which activates protein kinase C (PKC) (Nishizuka 
et al., 1991). 
It has been postulated that the basis for the down-regulation of the 5-HT 2A 
receptor following chronic treatment with antidepressants occurs at target sites 
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distal to the 5-HT2A receptor along its signal transduction pathway (Rasenick et 
al., 1996). Possible sites of alteration following chronic antidepressant treatment 
include: 1) receptor G-protein coupling; 2) G-protein expression; 3) G-protein 
effector coupling to PLC and; 4) effector expression (Rasenick et al., 1996). 
Facilitation of NMDA responses by 5-HT appears to depend on a rise in the 
intracellular Ca2+ concentration of cortical neurons (Rahman and Neuman, 1996). 
Thus, the loss of 5-HT2A receptor activity following chronic treatment with 
imipramine, fluoxetine or acute mianserin exposure could result from the 5-HT2A 
receptor becoming un-coupled from its G-protein system. This could account for 
the substantial reduction in functional 5-HT2A receptor activity compared to 
moderate reductions of 5-HT2 binding with imipramine and mianserin and little 
or no reduction in binding with fluoxetine. Preliminarily observations indicate 
that chronic fluoxetine does not alter the facilitation ofNMDA responses induced 
by carbachol (Payne and McNeil, unpublished observations). This suggests that 
loss of signal transduction following antidepressant exposure is associated with 
the 5-HT2A receptor and is not a generalized phenomenon. On the other hand I 
have observed a reduction in histamine H1 receptor-mediated facilitation of 
NMDA responses following chronic, but not acute, exposure to fluoxetine 
(Payne, unpublished observation). This may again suggest an un-coupling of the 
61 
receptor from its associated 0-protein. 
Alterations in 5-HT 2A mediated responses associated with PKC, which 
could be important in the mechanism underlying the therapeutic response of 
antidepressants have been observed. PKC phosphorylates cellular proteins (Mann 
et al., 1995) and is associated with 5-HT 2A receptor-triggered signals (Nishizuka, 
1988). PKC activity is significantly altered following chronic tluoxetine or 
desipramine exposure as well the PKC response to the 5-HT2A agonist (±)-1-(2,5-
dimethoxy-4-iodophenyl)-2-aminopropane (Mann et al., 1995). In senescent 
animals, the 5-HT 2A receptor mediated facilitation is absent whereas the 
facilitation by a- adrenoceptors, muscarinic receptors and metabotrophic 
glutamate receptors remains intact (Rahman et al., 1995). The 5-HT 2A facilitation 
is restored following application of PKC inhibitors (Rahman et al., 1995). 
Following the chronic administration of antidepressants such as an SSRI, PKC 
activity may be reduced, thus, the inhibitory feedback ofPKC on 5-HT 2A receptors 
(Roth et al., 1990) would be lost. Therefore, overstimulation of the 5-HT2A 
receptor may result in receptor down-regulation. 
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4.4 5-HT,A-5-HTZA Receptor Interactions: 
Based on results from the present study one possible mechanism mediating 
the therapeutic response of antidepressants is an interaction between cortical 5-
HT1A and 5-HT 2Areceptors. It is well known that 5-HT 1Aand 5-HT 2Areceptors are 
co-localized on the same cortical neurons (Araneda and Andrade, 1991 ). 
Therefore, increases in 5-HT concentration would not exert any stable change in 
the firing rate of the postsynaptic neuron (Borsini. 1994) and a balance must be 
achieved between the effects mediated by each receptor (Araneda and Andrade, 
1991 ). Stimulation of inhibitory neurotransmission in the cortex by activation of 
postsynaptic 5-HT1A receptors may not be sufficient to reduce the enhanced 5-
HT 2A activity found in depressed individuals. 
Another aspect of chronic antidepressant treatment is the desensitization 
of somatodendritic 5-HT1A autoreceptors 5-H-;J;. terminal receptors which 
mediate the amount of 5-HT released (Blier and de Montigny, 1994). When 
imipramine or fluoxetine is first administered there is an increase of 5-HT in the 
synaptic cleft due to blockade of 5-HT uptake (Blier et al., 1994 ). This increased 
5-HT activates somatodendritic 5-HT1A autoreceptors that in part control the firing 
rate of the DR. DR firing is reduced and hence less 5-HT is released in the 
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forebrain. Over approximately 14 days the DR adapts and returns to its normal 
firing rate (Blier et al., 1994). Moreover, following administration offluoxetine 
and imipramine, desensitization of both somatodendritic and terminal 5-HT1A 
autoreceptors coupled with a normal firing DR results in greater 5-HT release per 
impulse and increased amounts of 5-HT therefore act at postsynaptic sites 
(Borsini, 1994). Increased synaptic 5-HT may result in chronic activation of 
cortical5-HT2A receptors and therefore down-regulation (Paul et al., 1988). In this 
state there would be a shift in the balance between the 5-HT1A receptor mediated 
hyperpolarization and the 5-HT2Areceptor mediated depolarization favouring the 
5-HT1A hyperpolarization (Borsini, 1994). 
It is proposed that the net result of all three antidepressants examined is an 
increase in inhibitory 5-HT neurotransmission. Some evidence for this suggestion 
is seen in the experiments with mianserin. Foil owing acute administration of 
mianserin, facilitation of the NMDA response by 5-HT (30J.!M) is reduced to less 
than the NMDA control response. This is consistent with previous reports that(±)-
8-hydroxy-dipropylaminotetralin (8-0H-DPAT), a 5-HT1A receptor agonist, 
reduces the NMDA induced depolarizations (Rahman and Neuman, 1993). Thus, 
the smaller facilitation following mianserin may reflect the activation of 5-HT1A 
receptors, i.e., the balance shifts away from excitatory cortical 5-HT2A receptors 
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towards inhibitory 5-HT lA receptors. A possible explanation of why this is not 
observed with pretreatment with imipramine or fluoxetine is that mianserin acts 
directly on the 5-HT2A receptor. In contrast, imipramine and fluoxetine down-
regulate the receptor due to increased release of 5-HT. The later phenomenon 
may be insufficient to show the 5-HT lA receptor effect in my paradigm. 
Thus, with reduced functionality at postsynaptic 5-HT 2A receptors and 
increased 5-HT release due to desensitization of presynaptic autoreceptors or 
direct 5-HT2A down-regulation would result in increased activity at postsynaptic 
5-HT1A receptors. The net result would be an increase in 5-HT inhibitory 
neurotransmission, reversing the excitatory deficiency mediated via an up-
regulation of postsynaptic 5-HT2A receptors and thereby returning 5-HT activity 
to the "normal" level. 
Recently, a new antidepressant, BIMT 17, has begun clinical trials. BIMT 
17 is novel in that it acts as both a 5-HT1A agonist and 5-HT 2A antagonist (Borsini, 
1994 ). It might be expected that since these actions are occurring simultaneously 
a faster onset of the therapeutic response would be achieved. Preliminary clinical 
trials with BIMf 17 demonstrate a faster onset in the therapeutic response (Peter 
Thompson, personal communication). 
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4.5 Conclusions: 
Chronic antidepressant exposure to imipramine or fluoxetine or acute 
• exposure to mianserin reduces cortical 5-HT 2A receptor activity as detennined by 
a loss of5-HT stimulated facilitation of the mviDA depolarization. This functional 
loss appears to reflect changes at the 5-HT 2A receptor and appears unrelated to a 
change in the NMDA receptor. Chronic ECT exposure appears to have no 
functional effect on cortical 5-HT 2A receptors. This suggests that down-regulation 
of 5-HT 2A receptors may be involved in mediating the therapeutic response and 
that the mechanism involved may be via enhancement of inhibitory 5-HT 
neurotransmission through cortical 5-HT lA receptors. 
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4.6 Future Research: 
Although this study did address the question of whether 5-HT 2A receptors 
were functionally altered following treatment with antidepressants, further 
experiments are needed to fully answer the question of what role 5-HT 2A receptors 
and other receptors play in depression. 
1. Despite the use of antidepressants, these rats were not depressed and 
presumably had a normal 5-HT system prior to the administration of the 
antidepressant. In order to eliminate questions about the validity ofthe 5-HT2A 
functional down-regulation following antidepressant exposure in normal subjects, 
a definitive model of depression is required for full assessment of the functional 
role of 5-HT 2A receptors. 
2. There are a number of limitations associated with using cortical wedges 
in investigating the functionality of 5-HT 2A receptors. They include: 1) receptor 
desensitization which allows for only one agonist exposure per wedge; 2) indirect 
effects due to the grease-seal; 3) the number ofNMDA receptors activated with 
each exposure of drug and; 4) the use of facilitation ofNMDA responses as an 
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assessment of 5-HT 2A receptor activity. A more specific electrophysiological 
technique would reduce these problems. 
3. It would be naive to think that only the 5-HT system is involved in the 
mediation of the therapeutic response to antidepressants. Thus. a careful functional 
assessment of the interaction of 5-HT 2A receptors with other receptor systems 
would further our understanding of the mechanisms underlying the therapeutic 
response of antidepressants. 
4. A concentration-response curve addressing the time course of changes in 
5-HT zA functionality over a 14 day period would further the understanding of 
when 5-HT 2A receptor down-regulation occurs and how it relates to the onset of 
the therapeutic response. 
S. Finally, the mechanism underlying the possible antidepressant effects of 
ECT need to be addressed to determine if indeed ECT is an valid antidepressant 
and if so what are the mechanisms that underly its action. 
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